In Reply We thank García-Perdomo and Calle and Phuong et al for their comments regarding the interpretation of systematic reviews to better guide the treatment of Kawasaki disease (KD). Refractory KD resistant to the standard intravenous immunoglobulin treatment has been the focus of research on account of its high risk associated with coronary artery abnormalities (CAA).1,2 Novel adjunctive treatment modalities have increased during the past decade including corticosteroids.3
Dong Y, Chen S. Caution in Generalizing the Use of Adjunctive Primary Corticosteroids in Kawasaki Disease to Unselected Non-Japanese Populations—Reply. JAMA Pediatr. 2017;171(4):398–399. doi:10.1001/jamapediatrics.2016.5154
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: